Radioimunoterapia: uma abordagem terapêutica promissora no tratamento do carcinoma do ovário

Abstract

Ovarian carcinoma is the fifth leading cause of cancer death in women and is the leading cause among gynecologic malignancies. Factors such as the molecular heterogeneity of ovarian tumors and initial diagnosis at advanced stages hamper effective disease treatment. Given the ineffectiveness of current treatments, the development of newer therapeutic modalities for effective ovarian cancer treatment is still needed. Radioimmunotherapy that combines the use of monoclonal antibodies against tumor-associated antigens with the cytotoxic properties of therapeutic radionuclides could be one of these approaches. The potential of monoclonal antibodies to complement current treatment protocols may bring a significant improvement to the overall therapeutic outcomes of the disease. The aim of the present review is to give an overview of published clinical trials of radioimmunotherapy for the treatment of ovarian carcinoma